Description
An ω-3 endocannabinoid epoxide and CB receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively); reduces the viability of 143B metastatic osteosarcoma cells at 25 µM; decreases the production of IL-6 and increases LPS-induced production of IL-10 in BV-2 microglia at 2.5-10 µM; decreases LPS-induced cytotoxicity in BV-2 microglia at 5-10 µM; decreases nitrite production at 7.5 µM, an effect that can be partially reversed by AM630 and GW 9662; induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 µM); tube formation by HMVECs
Formal name: 18-(3-ethyl-2-oxiranyl)-N-(2-hydroxyethyl)-4Z,7Z,10Z,13Z,16Z-octadecapentaenamide
Synonyms: 19,20-DHEA epoxide|19,20-EDP epoxide|19,20-EDP-EA|19,20-epoxy Docosapentaenoic Acid Ethanolamide
Molecular weight: 387.6
CAS: 2123485-34-5
Purity: ≥98%
Formulation: A solution in ethanol
Product Type|Biochemicals|Lipids|Docosanoids||Product Type|Biochemicals|Lipids|Fatty Amides||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cardiovascular System|Vasculature|Angiogenesis||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Cytochrome P450 Pathways||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids